At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 133 enrolled
Drug / intervention
Testosterone enanthate auto-injectorcombination
Likely dose
Testosterone enanthate auto-injector 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
In Brief
A Phase 3 clinical trial evaluating Testosterone enanthate auto-injector for Hypogonadism. Completed, enrolled 133 participants across 20 sites.
Detailed Summary
Evaluation of safety of a concentration controlled testosterone enanthate QuickShot Testosterone regimen administered subcutaneously once each week to adult males with hypogonadism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedJul 2015
Primary CompletionJun 2016
TodayJul 2026
First PostedJul 22, 2015
Enrollment StartJul 1, 2015
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.9 years ago
Interventions
Testosterone enanthate auto-injectorcombination
Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels